709 related articles for article (PubMed ID: 23891860)
21. Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability.
Cai J; Wu L; Qi X; Shaw L; Li Calzi S; Caballero S; Jiang WG; Vinores SA; Antonetti D; Ahmed A; Grant MB; Boulton ME
PLoS One; 2011 Mar; 6(3):e18076. PubMed ID: 21464949
[TBL] [Abstract][Full Text] [Related]
22. Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.
Deissler HL; Busch C; Wolf A; Rehak M
Sci Rep; 2022 Jul; 12(1):12493. PubMed ID: 35864147
[TBL] [Abstract][Full Text] [Related]
23. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
[TBL] [Abstract][Full Text] [Related]
24. VEGF modulation of retinal pigment epithelium resistance.
Ablonczy Z; Crosson CE
Exp Eye Res; 2007 Dec; 85(6):762-71. PubMed ID: 17915218
[TBL] [Abstract][Full Text] [Related]
25. Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.
Jäckle A; Ziemssen F; Kuhn EM; Kampmeier J; Lang GK; Lang GE; Deissler H; Deissler HL
J Diabetes Res; 2020; 2020():2450781. PubMed ID: 32566677
[TBL] [Abstract][Full Text] [Related]
26. Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium.
Brankin B; Campbell M; Canning P; Gardiner TA; Stitt AW
Exp Eye Res; 2005 Jul; 81(1):22-31. PubMed ID: 15978251
[TBL] [Abstract][Full Text] [Related]
27. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
[TBL] [Abstract][Full Text] [Related]
28. Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A
Pang V; Bates DO; Leach L
Clin Sci (Lond); 2017 Dec; 131(23):2763-2775. PubMed ID: 29054861
[TBL] [Abstract][Full Text] [Related]
29. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
30. Response to anti-VEGF-A treatment of endothelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Exp Eye Res; 2016 May; 146():128-136. PubMed ID: 26771090
[TBL] [Abstract][Full Text] [Related]
31. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
32. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly.
Wang W; Dentler WL; Borchardt RT
Am J Physiol Heart Circ Physiol; 2001 Jan; 280(1):H434-40. PubMed ID: 11123261
[TBL] [Abstract][Full Text] [Related]
33. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells.
Spoerri PE; Afzal A; Li Calzi S; Shaw LC; Cai J; Pan H; Boulton M; Grant MB
Mol Vis; 2006 Jan; 12():32-42. PubMed ID: 16446700
[TBL] [Abstract][Full Text] [Related]
34. Glucocorticoids exert differential effects on the endothelium in an in vitro model of the blood-retinal barrier.
van der Wijk AE; Canning P; van Heijningen RP; Vogels IMC; van Noorden CJF; Klaassen I; Schlingemann RO
Acta Ophthalmol; 2019 Mar; 97(2):214-224. PubMed ID: 30168271
[TBL] [Abstract][Full Text] [Related]
35. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin-induced vascular hyperpermeability through tight junction disruption in diabetic retina.
Someya H; Ito M; Nishio Y; Sato T; Harimoto K; Takeuchi M
Exp Eye Res; 2022 Jul; 220():109094. PubMed ID: 35490836
[TBL] [Abstract][Full Text] [Related]
37. Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):83-94. PubMed ID: 30367290
[TBL] [Abstract][Full Text] [Related]
38. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.
Fan Y; Liu K; Wang Q; Ruan Y; Ye W; Zhang Y
Exp Eye Res; 2014 Oct; 127():104-16. PubMed ID: 24910901
[TBL] [Abstract][Full Text] [Related]
39. miR-15a/16 inhibits TGF-beta3/VEGF signaling and increases retinal endothelial cell barrier proteins.
Ye EA; Liu L; Steinle JJ
Vision Res; 2017 Oct; 139():23-29. PubMed ID: 28774775
[TBL] [Abstract][Full Text] [Related]
40. Partial characterization of the human retinal endothelial cell tight and adherens junction complexes.
Russ PK; Davidson MK; Hoffman LH; Haselton FR
Invest Ophthalmol Vis Sci; 1998 Nov; 39(12):2479-85. PubMed ID: 9804158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
